Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Harvard Business School
Medtronic
AstraZeneca
Boehringer Ingelheim

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CERC-301

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for CERC-301?

CERC-301 is an investigational drug.

There have been 6 clinical trials for CERC-301. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Massachusetts General Hospital.

There are seven US patents protecting this investigational drug and eighty-one international patents.

Recent Clinical Trials for CERC-301
TitleSponsorPhase
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?Cerecor IncPhase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?National Institute on Drug Abuse (NIDA)Phase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?Office of Research on Women's Health (ORWH)Phase 2

See all CERC-301 clinical trials

Clinical Trial Summary for CERC-301

Top disease conditions for CERC-301
Top clinical trial sponsors for CERC-301

See all CERC-301 clinical trials

US Patents for CERC-301

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CERC-301   Start Trial Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited (Grand Cayman, KY)   Start Trial
CERC-301   Start Trial Compounds, compositions and methods CERECOR, INC. (Baltimore, MD) MERCK SHARP & DOHME CORP. (Rahway, NJ)   Start Trial
CERC-301   Start Trial 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED (Grand Cayman, KY)   Start Trial
CERC-301   Start Trial Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited (Grand Cayman, KY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CERC-301

Drugname Country Document Number Estimated Expiration Related US Patent
CERC-301 Argentina 100733 2034-06-04   Start Trial
CERC-301 Australia 2015271719 2034-06-04   Start Trial
CERC-301 Canada 2950285 2034-06-04   Start Trial
CERC-301 China 106795163 2034-06-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Dow
Harvard Business School
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.